Geranylgeranyl diphosphate synthase (GGDPS), the source of the isoprenoid donor in protein geranylgeranylation reactions, has become an attractive target for anti-cancer therapy due to the reliance of cancers on geranylgeranylated proteins. Current GGDPS inhibitor development focuses on optimizing the drug-target enzyme interactions of nitrogen-containing bisphosphonate-based drugs. To advance GGDPS inhibitor development, understanding the enzyme structure, active site, and ligand/product interactions is essential. Here we provide a comprehensive structure-focused review of GGDPS. We reviewed available yeast and human GGDPS structures and then used AlphaFold modeling to complete unsolved structural aspects of these models. We delineate the elements of higher-order structure formation, product11 substrate binding, the electrostatic surface, and small molecule inhibitor binding. With the rise of structure-based drug design, the information provided here will serve as a valuable tool for rationally optimizing inhibitor selectivity and effectiveness.

Original languageEnglish (US)
JournalMolecular cancer therapeutics
Issue number1
StatePublished - Jan 10 2024


  • Geranylgeranyl diphosphate synthase
  • electrostatic surface
  • multiple myeloma
  • pancreatic ductal adenocarcinoma
  • small molecule inhibitors
  • substrate-product binding

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Structural insight into geranylgeranyl diphosphate synthase (GGDPS) for cancer therapy'. Together they form a unique fingerprint.

Cite this